Market Potential For Mirv and 632? | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  51889 of 52052  at  2/28/2021 2:11:24 PM  by

pierre piav


 In response to msg 51888 by  EFJ61
view thread

Re: Market Potential For Mirv and 632?

 Per corp presentation
8,900 patients diagnosed annually.
 
632
BPDCN  500 - 1000 cases in US annually, of which 60 -70% become relapsed/refactory
so that puts that at 300-700 in US, seeking alpha wild guess was to double that for international markets.   See slide 16
 
For AML, and especially for the combo, I think it is way to early try to even guess at size of market.  Still in ph1b/2 right?  If a combo turns out to be the MacDaddy of SOC, i would imagine it would be a substantial market opportunity. 
 
for annual cases and deaths:
 
For treatment success:
 
 
Very good response to chemo, it looks like...but I would imagine there is a market for Minimal Residual Disease patients.
 
For options post chemo:
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
51890 Re: Market Potential For Mirv and 632? k12now 0 2/28/2021 3:50:12 PM
51891 Re: Market Potential For Mirv and 632? MRHIROLLER 0 2/28/2021 5:00:33 PM
51893 Re: Market Potential For Mirv and 632? DocR 1 2/28/2021 5:39:11 PM








Financial Market Data provided by
.
Loading...